Interleukin 12 a Key Immunoregulatory Cytokine in Infection Applications by Hamza, Therwa et al.
Int. J. Mol. Sci. 2010, 11, 789-806; doi:10.3390/ijms11030789 
 
International Journal of 
Molecular Sciences 
ISSN 1422-0067 
www.mdpi.com/journal/ijms 
Review 
Interleukin 12 a Key Immunoregulatory Cytokine in Infection 
Applications 
Therwa Hamza 
1,2, John B. Barnett 
3 and Bingyun Li 
1,2,4,5,* 
1  Biomaterials, Bioengineering & Nanotechnology Laboratory, Department of Orthopaedics, School 
of Medicine, West Virginia University, Morgantown, WV 26506, USA;  
E-Mail: thamza@hsc.wvu.edu (T.H.) 
2  Pharmaceutical and Pharmacological Sciences Graduate Program, Health Sciences Center, West 
Virginia University, Morgantown, WV 26506, USA  
3  Department of Microbiology, Immunology, and Cell Biology, West Virginia University, 
Morgantown, WV 26506, USA; E-Mail: jbarnett@hsc.wvu.edu (J.B.B.) 
4  WVNano Initiative, Morgantown, WV 26506, USA 
5  Department of Chemical Engineering, College of Engineering and Mineral Resources, West 
Virginia University, Morgantown, WV 26506, USA 
*  Author to whom correspondence should be addressed; E-Mail: bli@hsc.wvu.edu;  
Tel.: +1-304-293-1075; Fax: +1-304-293-7070. 
Received: 9 January 2010 / Accepted: 24 February 2010 / Published: 26 February 2010 
 
Abstract:  Interleukin 12 (termed IL-12p70 and commonly designated IL-12) is an 
important immunoregulatory cytokine that is produced mainly by antigen-presenting cells. 
The expression of IL-12 during infection regulates innate responses and determines the 
type of adaptive immune responses. IL-12 induces interferon-γ (IFN-γ) production and 
triggers CD4
+ T cells to differentiate into type 1 T helper (Th1) cells. Studies have 
suggested that IL-12 could play a vital role in treating many diseases, such as viral and 
bacterial infections and cancers. The unique heterodimeric structure, which IL-12 shares 
with its family members including IL-23, IL-27, and IL-35, has recently brought more 
attention to understanding the mechanisms that regulate the functions of IL-12. This article 
describes the structure and biological activities of IL-12 in both the innate and adaptive 
arms of the immune system, and discusses the applications of IL-12 in treating and 
preventing infections.  
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1. Introduction 
It is well-established that CD4
+ T helper (Th) cells can be divided, besides T regulatory and Th17, 
into two major subsets: Th1 and Th2, based on their patterns of cytokine production. Th1 cells mainly 
secrete interleukin 2 (IL-2), IFN-γ, and IL-12, whereas Th2 cells secrete IL-4, IL-5, and IL-10 [1]. 
Functionally, Th1 cells predominantly promote cell-mediated immunity and help in clearance of 
intracellular pathogens; Th2 cells are responsible for humoral immunity protecting against 
extracellular invaders. The balance between IL-12, favoring Th1 responses, and IL-4, favoring Th2 
responses, determines the early preference expressed in the immune response. 
IL-12 has multiple biological functions and importantly, it bridges the early nonspecific innate 
resistance and the subsequent antigen-specific adaptive immunity [2]. IL-12 was first identified as a 
product of Epstein-Barr virus (EBV)-transformed human B cell lines. IL-12 was previously known as 
T cell differentiation factor (TCDF) or natural killer cell stimulatory factor (NKSF). IL-12 used to be 
the only known heterodimeric cytokine, but it is now a part of a family consisting of several other 
members including IL-23, IL-27, and the recently identified IL-35. These new molecules have been 
found to play distinct cellular and functional roles in Th1 development [3]. In this article, the structure 
and functions of IL-12 are reviewed and the role of IL-12 in regulating immune responses and treating 
infections is discussed.  
2. IL-12 Molecular Structure and Signaling Pathway 
2.1. IL-12 Molecular Structure 
IL-12 is a key immunoregulatory cytokine [2,4,5] with a molecular weight of 70 kDa (Figure 1), 
composed of two covalently-linked subunits, IL-12p35 (35 kDa) and IL-12p40 (40 kDa), each of 
which is expressed on different chromosomes. The sequence of the p35 gene is homologous to that of 
IL-6 and granulocyte-colony stimulating factor [6]. The sequence of the p40 chain has a homology to 
the extracellular domain of the IL-6 receptor (IL-6R) α-chain and the ciliary neurotropic factor [7]. 
This explains some of the redundant actions of these cytokines. 
Although p35 transcripts are found in many cell types, free p35 is not secreted without the p40 
subunit. IL-12p40 is produced predominantly by activated monocytes, macrophages (MФs), 
neutrophils, and dendritic cells (DCs). It has been suggested that in mice, but not in humans, IL-12p40 
homodimers antagonize IL-12p70 activity by binding to the β1 subunit of the IL-12 receptor [8–10]. 
Also, IL-12p40 has been shown to act as a chemoattractant for MФs and promotes the migration of 
stimulated dendritic cells [11]. The p40 subunit is associated with several pathogenic inflammatory 
responses such as silicosis, graft rejection and asthma, but it is also found to be protective in a 
mycobacterial infection model [11]. 
The biological activities of IL-12 are mediated via binding to a membrane receptor complex which 
is also composed of two subunits: IL-12R β1 and IL-12R β2. Both of the subunits are members of the 
class I cytokine receptor family, which includes IL-6, IL-11, and leukocyte inhibitory factor related to 
glycoprotein gp130 [12,13]. There is a high level of conservation, with a 68% amino acid sequence 
homology, between mouse and human IL-12R β2 proteins, and a 54% sequence identity homology 
between the mouse and human IL-12R β1 [12]. Both receptor chains are required to mediate maximal Int. J. Mol. Sci. 2010, 11                 
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signaling; however, the two chains have independent roles. IL-12R β1 is required for high-affinity 
binding to the IL-12p40 subunit and it is associated with the Janus kinase (Jak) family member Tyk-2, 
while the IL-12R β2 chain mediates signal transduction via three tyrosine residues that act as a 
docking site for STAT4 and is associated with Jak-2. IL-12R β2 recognizes either the heterodimer  
IL-12 or the IL-12p35 subunit and is expressed, not on naive T cells, at low levels after T cell receptor 
stimulation. Expression of this receptor subunit is critically influenced by IL-12 and type 1 IFNs [5]. 
The initial expression of functional IL-12Rs is further enhanced when IL-12 is present at the time of 
priming, working as a positive feedback loop regulator [14].  
Figure 1. Crystal structure of IL-12. IL-12 is composed of a bundle of four alpha helices. It 
is a heterodimeric cytokine encoded by two separate genes, IL-12p35 and IL-12p40. 
Obtained from the Protein Data Bank (PDB: 1F45). 
 
 
2.2. IL-12 Family Members 
The IL-12 family has expanded recently to include members like IL-23, IL-27, and IL-35. IL-12 
and these new family members play critical roles in Th1 cell development [4,15]. Figure 2 summarizes 
the structure and biological properties of these major IL-12 family members.  
2.2.1. Interleukin-23 
IL-23 is a proinflammatory cytokine that is closely related in structure to IL-12; they both share the 
p40 subunit that is able to build a disulfide bridge complex with the p19 subunit to form the 
biologically active molecule. The p40-p19 complex is mainly secreted by activated intestinal antigen 
presenting cells, such as DCs and monocytes [15]. Similar to IL-12 signaling, IL-12R β1 is required 
for high affinity binding to p40, whereas IL-23R has a cytoplasmic STAT4 binding domain for signal 
transduction. However, STAT3/STAT4 heterodimers in IL-23 instead of STAT4 homodimers in IL-12 
are translocated to the nucleus to induce specific gene expression [16].  
The main role of IL-23 involves the stimulation of Th17 cells to produce IL-17 [3]; it also induces 
the proliferation of memory T cells [17]. Unlike IL-12, IL-23 does not induce significant production of 
IFN-γ and in the absence of IL-23, IFN-γ production and Th1 differentiation are still found to be 
normal [15].  Int. J. Mol. Sci. 2010, 11                 
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2.2.2. Interleukin-27 
IL-27 is another heterodimeric cytokine composed of the p28 subunit and the p40-related protein 
Epstein-Barr virus-induced gene 3 (EBi3). IL-27 activities are driven via one receptor that was 
described recently with some homology to gp130, known as TCCR or WSX-1 [18]. Signaling through 
TCCR or WSX-1 is required for the early initiation of a Th1 response, but is not necessary for the 
maintenance of Th1 responses [18]. The signaling pathway initiated by IL-27 activates Jak-1 and Jak-2 
molecules. However, only STAT1 and STAT3 are critical to IL-27 bioactivity, and STAT3 rather than 
STAT1 is required for IL-27-induced proliferation [19].  
IL-27 is rapidly produced by human phagocytic cells and DCs after their activation [18]. IL-27 is 
involved in early Th1 initiation, is able to induce proliferation of naive but not memory T cells, and 
can synergize with IL-12 in IFN-γ production [19]. 
2.2.3. Interleukin-35 
IL-35 was discovered very recently [20]. This heterodimeric cytokine is composed of the p35 
subunit and the p40-related protein EBi3. The IL-35 R complex has not been characterized yet, but it is 
possible that it may be composed of the receptors known for IL-27 and IL-12, either gp130 or WSX-1 
and IL-12R β2. 
Figure 2. The IL-12 cytokine family; structural and biological characteristics. Reprinted 
from Ref. [13]. 
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Within the CD4
+ T-cell population, IL-35 is expressed by resting and activated T regulatory cells 
(Tregs) but not activated T cells. Loss of IL-35 expression results in reduced immune suppression by 
Tregs. IL-35 appears to function as an anti-inflammatory molecule by inhibiting T-cell proliferation. It 
is suggested that IL-35 can suppress Th17 development in vivo [21]; however, further studies are 
required to fully understand the exact mechanism behind these functions.  
2.3. IL-12 Signaling Pathway 
The signaling pathway of IL-12 is described in Figure 3. On binding of IL-12 to the IL-12R 
complex, activation of Jak kinases (Tyk-2 and Jak-2) occurs, leading to phosphorylation of the 
receptor, which becomes a binding site for STAT4 proteins that are rapidly recruited to the receptor 
and phosphorylated on their tyrosine residues by the Jak kinases. Tyrosine phosphorylation of STAT4 
proteins induces their homodimerization and translocation to the nucleus where they bind to specific 
sequences and regulate gene transcription (Figure 3). In Th1 and NK cells, IL-12 mainly induces 
STAT4 activation. In addition, STAT1, STAT3, and STAT5 can also be activated by IL-12 signaling 
[13,22]. Studies have shown that IFN-γ increases the transcription factor T-bet activity, which was 
originally shown to be induced in Th1 cells [23]. T-bet response to IFN-γ leads to the up-regulation of 
IL-12R β2 surface expression and allows for Th1 cell responsiveness to IL-12 [23,24]. More recent 
studies showed that T-bet negatively regulates GATA-3 expression, the main regulator of Th2 cell axis 
[25]. In contrast, the Th2 cytokine IL-4 reduces IL-12R β2 expression and thus leaves Th2 cells non-
responsive [26]. The opposite effects of IFN-γ and IL-4 on IL-12R β2 expression may contribute to the 
commitment of Th1/Th2 differentiation. Priming of macrophages with IFN-γ increases cellular 
responsiveness to inflammatory stimuli, including IFN-γ itself, which activates direct microbicidal 
functions including the production of reactive oxygen species and TNF-α and promotes
 the antigen 
(Ag) processing and presentation capacities of macrophages. Also, IFN-γ plays a role in the regulation 
of T cell proliferation and activity [27]. 
Recently, Toll like receptors (TLRs) are believed to play an important role in the balance between 
production of IL-12 and its family members (e.g., IL-23 and IL-27) [28]. TLRs are part of the innate 
immune system that recognizes pathogen antigens causing a proper immune response activation. The 
binding of pathogen-associated molecular patterns to different TLRs can stimulate the production of 
IL-12 family members. However, engagement of two or more TLRs can induce more significant levels 
of IL-12 than activation of a single TLR; coupling of TLR8 ligands with TLR3 or TLR4 induces 
higher levels of IL-12 than stimulation by individual TLR ligands [29]. Importantly, selective 
production of each of IL-12 family member is regulated by triggering specific TLRs. For instance, the 
activation of TLR4 can induce the production of both IL-12 and IL-23, whereas activation of TLR2 
induces high levels of IL-23 but not IL-12 [30]. On transcription regulation level, signaling through 
TLRs leads to different gene-inducing programs. TLRs (except TLR3) bind to the adapter molecule 
MyD88 and result in nuclear factor-κB (NF-κB) activation. This signaling pathway has been shown to 
activate the genes encoding the subunits of IL-12, IL-23, and IL-27 [31–33]. Several other 
transcription factors, such as IFN-regulatory factors (IRFs) are involved in IL-12 production, including 
IRF1, IRF3, and IRF7. Also, IFN-γ signaling through IRF1 and IRF8 triggers TLR-induced IL-12 
production [28].  Int. J. Mol. Sci. 2010, 11                 
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Figure 3. IL-12 signaling pathway. IL-12 activates the Jak/STAT pathway. Following 
binding of IL-12p40 and IL-12p35 to IL-12R β1 and IL-12R β2, respectively, Jak-2 and 
Tyk-2 get transphosphorylated. Phosphorylated IL-12R β2 binds to STAT4 which will then 
dimerize with another STAT4 molecule. STAT4 homodimers translocate to the nucleus 
and promote IFN-γ gene transcription. T-bet is another transcription factor that plays a role 
in Th1 development and IFN-γ production. The IL-12 and IFN-γ induce the activity and 
proliferation of MФs, NK cells, and T cells, which also secrete IL-12. Modified from  
Ref. [34].  
 
3. IL-12 Biological Activities 
IL-12 is produced mainly by DCs, MФs, monocytes, neutrophils, microglia cells and, to a lesser 
extent, by B cells (Figure 4); human but not murine B cells were found to produce IL-12 following 
CD40 ligation [35]. Non-immune cells such as infected-keratinocytes and osteoblasts, epithelial and 
endothelial cells have also been shown to produce some amounts of this cytokine [36,37]. Pathogen-
associated molecular patterns such as lipopolysaccharide (LPS), teichoic acid, peptidoglycan, and 
bacterial CpG DNA, can induce IL-12 production. The production of IL-12 is regulated by positive 
and negative feedback mechanisms involving Th1 cytokines (e.g., IFN-γ), Th2 cytokines (e.g., IL-10), 
and type 1 IFN (Figure 4) [38,39]. Int. J. Mol. Sci. 2010, 11                 
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Figure 4. Summary of the biology of IL-12 [14]. The main physiological producers of  
IL-12 are phagocytes (monocytes/MФ and neutrophils) and DCs in response to pathogens 
(bacteria, fungi, intracellular parasites and viruses) through TLRs and other receptors, to 
membrane-bound and soluble signals from activated T cells and NK cells, and to 
components of the inflammatory extracellular matrix (for example, low-molecular-weight 
hyaluronan) through CD44 and TLRs. The physiologically most important target cells of 
IL-12 are: haematopoietic progenitors, for which, in synergy with other colony-stimulating 
factors, IL-12 induces increased proliferation and colony formation; NK cells, NK T cells 
and T cells, for which IL-12 induces proliferation, enhancement of cytotoxicity and of the 
expression of cytotoxic mediators, and the production of cytokines, particularly IFN-γ, as 
well as favoring differentiation to cells that produce type-1 cytokines (Th1, TC1 and NK1 
cells); and B cells, for which IL-12, directly or through the effects of type-1 cytokines such 
as IFN-γ, enhances the activation and production of Th1-associated classes of 
immunoglobulin (for example, IgG2a in the mouse). CTL, cytotoxic T lymphocyte;   
GM-CSF, granulocyte macrophage colony-stimulating factor; RANKL, receptor activator 
of nuclear factor-κB ligand; SCF, stem-cell factor; TC1, T cytotoxic 1; TH1/Th1, T helper 
1; TNF, tumor-necrosis factor. Reprinted from Ref. [14]. 
 
 
IL-12 has multiple biological functions (Table 1) and it bridges innate and adaptive immunity.  
IL-12 induces differentiation of naive CD4
+  T cells to Th1 cells and activates NK cells. Upon 
activation, these cells produce IFN-γ and other type-1 cytokines [40]. IL-12 also protects CD4
+ Th1 
cells from antigen-induced apoptotic death [41]. IL-12 was found to have synergistic effects with  
IL-18 in developing Th1 cells, and IL-12 and IL-18 reciprocally upregulate each other’s receptors [5]. 
In addition, IL-12 plays a role in T cell trafficking and migration by inducing functional adhesion Int. J. Mol. Sci. 2010, 11                 
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molecules such as P- and E-selectin ligand expression on Th1 cells but not Th2 cells; therefore, these 
cells are selectively recruited to sites where Th1 immune responses are needed [42]. Studies also 
reported selective expression of CCR5 and CXCR3 when naive T cells were primed in the presence of 
IL-12 [40,43]. Stimulation of MФ-derived IL-12 also plays a major role in the induction of resistance 
in parasitic infestation [44]. 
The biological activity and quantity of IL-12 can be determined using molecular approaches. One of 
the first approaches for quantifying IL-12 was based on IL-12-induced proliferation of 
phytoheagglutinin (PHA)-stimulated lymphocytes [45]. Peripheral blood mononuclear cells activated 
with PHA along with IL-2 proliferate in response to IL-12. Enzyme-linked immunosorbent assay 
(ELISA) was also utilized to quantify specifically IL-12p40 and IL-12p70 [46]. In combination with 
ELISA, another approach, based on the ability of IL-12 to induce IFN-γ secretion from activated  
T-lymphoblasts, was developed and has been used to measure the biological activities of   
IL-12 [47,48]. 
Table 1. Main immunological functions of IL-12. 
• Promote naive CD4
+ T cells to differentiate into Th1 
• Enhance the generation and activity of cytotoxic T 
lymphocytes 
• Induce IFN-γ production by (i) NK cell, T cell, DC, 
and MФ, (ii) cooperating with B7/CD28 interaction, 
and (iii) synergizing with IL-18 
• Increase MФ antimicrobial activity 
• Prime DC activation to induce more IL-12 production 
• Induce functional adhesion molecule expression on 
Th1 cells and influence T cell trafficking 
4. IL-12 Therapeutic Applications in Infections 
IL-12 holds considerable promise as an immunotherapeutic agent because it plays a central role in 
regulating innate and adaptive immune responses, and synergizes with several other cytokines for 
increased immunoregulatory activities. Also, tipping the balance between the expression of IL-12 
family members may represent a novel strategy to control T-cell-mediated immune responses [28]. 
Animal and human studies have shown improved outcomes in treating or preventing infections based 
on the mechanisms of IL-12-dependent therapies. 
4.1. Viral Infections 
The role of IL-12 in promoting endogenous protective immune responses to viral infections has 
been attracting more attention with time. Many experimental models have been developed to test the 
potential effects of IL-12 and other immune mediators on the herpes simplex virus, influenza virus, 
human immunodeficiency virus (HIV), lymphocytic choriomeningitis virus, mouse cytomegalovirus, 
and many others [49]. Int. J. Mol. Sci. 2010, 11                 
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4.1.1. Herpes simplex virus  
In an in vivo herpes simplex virus-1 (HSV-1) mouse model, sustained expression of IL-12 was 
induced by the virus. This local IL-12 production was considered to cause an immunopathological 
response in the mouse eye environment due to Th1 immunity [50]. However, exogenous IL-12 showed 
a protective role and increased the resistance to infection in HSV-1-thermally injured mice because of 
the activation of viral-specific Th1 immunity [51]. Also, IL-12 and IL-18 were shown to play an 
important role in innate immunity against genital HSV-2 infection in a mouse model; the protection 
was mainly mediated by IFN-γ production [52]. 
4.1.2. Influenza virus 
CD4
+ T cells are important in controlling influenza A virus infection. CD4
+ T cells drive the 
induction and expansion of CTL against such viral pathogens. Earlier studies using the influenza virus 
system as a model showed that DCs induced effective CTL response without increasing endogenous 
IL-12 levels. Exogenous application of IL-12 was found to significantly enhance CTL activity [53]. 
Studies also demonstrated a combined effective role of IL-12 and DCs in enhancing CTL immunity to 
viral infection [53]. Influenza virus vaccination effectively protects individuals against serious 
complications through induction of humoral and cellular responses [54]. Interestingly, patients 
identified with genetic IL-12/23R β1 or IFN-γR deficiencies were found to develop immune responses 
to childhood vaccination [53]. Also, the influenza vaccination could induce humoral immunity and 
IFN-γ production in IL-12/23R β1 deficient patients [55]. These studies may imply that both IL-12 and 
IFN-γ play a significant role in fighting viral infections.  
4.1.3. Human immunodeficiency virus (HIV) 
HIV infection mainly induces Th2 immunity which, most of the time, is unable to clear the viral 
infection. Glycoprotein gp120 of HIV has been shown to induce IFN-γ dependent production of IL-12 
in cultured MФs. The use of IL-12 production and Th1 activation might contribute to decreased viral 
load and increased clearance of the infection [56]. However, phase I trials in HIV patients have shown 
moderate effects accompanied by some toxic responses [57].  
4.2. Bacterial Infections 
As a potent inducer of Th1 immune response and an important mediator between innate and 
adaptive immunity, IL-12 has potential clinical uses in treating and preventing bacterial infections. 
4.2.1. Bone infection 
Osteomyelitis is a bone infection characterized by the presence of necrotic bone tissue and 
increased osteoclast activity. It is commonly caused by Staphylococcus aureus (S. aureus), which is 
traditionally known as an extracellular pathogen; however, it has been shown that S. aureus can be 
internalized and live within a variety of host cells [58,59]. Internalization of S. aureus into the host 
cells could be an important pathogenicity factor for escaping the host immune system leading to Int. J. Mol. Sci. 2010, 11                 
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persistence of infection [60]. It was reported that mouse and human osteoblasts in vitro infected with 
S. aureus express high levels of IL-12 [37], and IL-12 and/or IL-23 knockout mice showed an 
increased susceptibility to bacterial, parasitic, and fungal infections [61]. The ability of S. aureus-
infected osteoblasts to elaborate bioactive IL-12, which may augment a Th1 immune response, has 
important implications for host defense against intracellular pathogens such as the internalized S. 
aureus, and such a mechanism would seem to be a significant advantage for the elimination of 
intracellular bacteria [60]. IL-12 may also play a critical role in the downregulation of S. aureus 
growth in vivo [62]. Of note, the role of IL-12 and Th1 cells in the development of cell-mediated 
inflammatory disorders is still not clear [28]. 
More recently, studies have shown that IL-12 may play a significant role in preventing 
osteomyelitis. A decrease in IL-12 production was observed upon pathogen-mediated ligation of MФ 
Fcγ or complement receptors [63,64]. This may indicate that there are cases in which regulation of  
IL-12 production can be affected by pathogens. Perhaps down-regulation of IL-12 has the potential to 
provide pathogens with a means of suppressing cell-mediated immunity. As a result, it may take a 
longer time to clear pathogens and lead to a higher risk of developing a bacterial infection. Meanwhile, 
IL-12 production was shown to decrease following trauma or major burns and results in decreased or 
delayed cell-mediated immune response and decreased resistance to infection [65–68].
 Exogenous 
application of IL-12, combined with nanotechnology drug delivery systems, may have restored the 
decreased IL-12 level and recovered the host’s cell-mediated immune response. It has been found to be 
effective in preventing open fracture-associated osteomyelitis [69,70]. The mechanism of protection is 
related to the enhancement of Th1 reactivity and activation of MФs in the early stage of surgery 
(Figure 5) [69]. The activation of MФs may lead to enhanced antigen presentation, phagocytosis, Fc 
receptor expression and nitric oxide and superoxide production [71]. As a result, these changes may 
substantially increase the ability of MФs to kill a wide variety of intracellular and extracellular 
bacteria and to enhance the development of long-term immunity to those pathogens [71]. 
It is worthy to note that different approaches can be utilized for IL-12 delivery. To name a few, 
intranasal administration of IL-12 has been used to eradicate osteosarcoma lung metastases [72], and 
intraperitoneal administration of IL-12 to treat ovarian cancer [73]. Also, IL-12 nanocoatings have 
been applied for prevention of bone infections [69,70], and IL-12 microspheres for tumor treatments 
[74]. IL-12 nanocoatings and microspheres may protect IL-12 from losing its bioactivity since IL-12 
has a short half-life of 12 hours [75] and IL-12 applied without a delivery vehicle may undergo rapid 
degradation. Also, studies have shown that treatments with 1000 ng/kg IL-12 in humans [76] and mice 
[77] were well tolerated.  
4.2.2. Tuberculosis  
Tuberculosis (TB) is a common and often deadly infectious disease caused by mycobacteria 
including  Mycobacterium tuberculosis,  Mycobacterium bovis,  Mycobacterium africanum, 
Mycobacterium canetti, and others. The chronic nature of Mycobacterium tuberculosis (Mtb) infection 
has led researchers to investigate the host’s immunity to respond to and control this disease. Previous 
reports involving TB infection models showed that the development of Th1 cells in response to IL-12 
production and subsequent induction of IFN-γ are key players in immunity to TB [78]. Exogenous  Int. J. Mol. Sci. 2010, 11                 
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IL-12 application was found to result in lower bacterial load and increased incidence of survival [79]. 
DC and Th1 activation and migration to the infected lungs were shown to control bacterial growth via 
IFN-γ–induced activation of phagocytes [80]. This immune response, however, may not be solely 
mediated by IL-12, as the other IL-12 family members (IL-23, IL-27, and IL-35) may also participate 
as well [11].  
Figure 5. Local IL-12 therapy stimulates Th cells to secrete Th1 cytokines. Exogenous  
IL-12 application creates an environment rich in IL-12 around the infection site. In such a 
local environment, newly activated Th cells, responding to the presence of bacteria, exit 
the blood and are influenced to become Th1 cells and secrete more Th1 cytokines and 
activate macrophages and NK cells. Activated macrophages will produce more IL-12 and 
via positive feedback, cell-mediated immunity can be promoted to battle bacteria thereby 
leading to the prevention of infection. Reprinted from Ref. [69]. 
 
5. Conclusions and Outlook 
The IL-12 family includes several important immunoregulatory cytokines. Among them, IL-12,  
IL-23, and IL-27 act on T cells to induce IFN-γ production and promote T cell expansion and 
differentiation, while IL-35 inhibits T cell proliferation. In the future, it would be of interest to dissect 
the signaling pathways by which these family members mediate their distinct effects on Th1 and  
Th2 responses.  
IL-12 has multiple biological activities, and it is a key factor that drives Th1 responses and IFN-γ 
production. Early application or production of IL-12 during infection may activate MФs and augment Int. J. Mol. Sci. 2010, 11                 
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a host’s cell-mediated immunity while shaping the ultimate antigen-specific immune responses. As a 
result, IL-12 may play a key role in protection against bacterial and viral infections, and IL-12 
immunotherapy could be of importance in the treatment of diseases where a Th1 response is desirable. 
Meanwhile, cytokines including IL-12 have a short in vivo half-life, and the development of advanced 
drug delivery systems [81-83] that can protect IL-12 from losing bioactivity would also be of interest.  
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